Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma
Arterial hypertension (HTN) is a class effect of anti-vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system...
Main Authors: | Lisa Derosa, Hassane Izzedine, Laurence Albiges, Bernard Escudier |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2016-11-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/298 |
Similar Items
-
Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
by: Karl Andersen
Published: (2009-03-01) -
Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01) -
Direct Renin Inhibitor is Better than Angiotensin II Receptor Blocker for Intrarenal Arterioles
by: Yohko Nagai, et al.
Published: (2016-08-01) -
Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study
by: Jae Hyun Bae, et al.
Published: (2021-05-01) -
THE PATHOPHYSIOLOGY RELATIONSHIP OF HYPERTENSION AND RENAL HYPERTENSION
by: Akmarawita Kadir
Published: (2018-02-01)